

# HEALTHY U MEDICAID

## PHARMACY PRIOR AUTHORIZATION REQUEST FORM

### LUNSUMIO™

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 801-213-1547.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have medical pharmacy prior authorization questions, please call for assistance: 833-981-0212

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

|               |              |                 |
|---------------|--------------|-----------------|
| Date:         | Member Name: | ID#:            |
| DOB:          | Gender:      | Physician:      |
| Office Phone: | Office Fax:  | Office Contact: |

Height/Weight:

***Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.***

**Product being requested:**  Lunsumio™ (mosunetuzumab-axgb)

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section.

| Questions  | Yes                      | No                       | Comments/Notes                      |
|--|--------------------------|--------------------------|-------------------------------------|
| 1. Does documentation show histologically confirmed diagnosis of relapsing or refractory follicular lymphoma grade 1, 2, or 3A?  | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |
| 2. Does the member have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1?   | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |
| 3. Does documentation show no response or refractory to at least 2 lines of systemic therapy, including both of the following: <ul style="list-style-type: none"> <li>• Anti-CD20 therapy</li> <li>• An alkylating containing regimen</li> </ul>   | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |
| 4. Does the member have current or past central nervous system (CNS) involvement?  | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |
| 5. For females with reproductive potential: <ul style="list-style-type: none"> <li>• Is there documentation of a negative pregnancy test prior to the start of therapy?</li> <li>• Has the member been counseled on the use of effective contraception during treatment and advised of the pregnancy risks associated with treatment?</li> </ul> | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |

#### REAUTHORIZATION

|   |                              |                             |                                     |
|---|------------------------------|-----------------------------|-------------------------------------|
| 1. Is the request for reauthorization of therapy?                                       | Yes <input type="checkbox"/> | No <input type="checkbox"/> |                                     |
| 2. Has the member had a complete response based on imaging and bone marrow examination? | <input type="checkbox"/>     | <input type="checkbox"/>    | <b>Please provide documentation</b> |

|  |                          |                          |                                     |
|--|--------------------------|--------------------------|-------------------------------------|
| 3. Does the member have a partial response on stable disease in response to treatment with Lunsumio™ after 8 cycles?   | <input type="checkbox"/> | <input type="checkbox"/> | <b>Please provide documentation</b> |
| <b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b> |                          |                          |                                     |
| Additional information:  |                          |                          |                                     |
| Physician Signature:   |                          |                          |                                     |

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-HU-M042  
 Origination Date: 03/01/2023  
 Reviewed/Revised Date: 03/15/2023  
 Next Review Date: 03/15/2024  
 Current Effective Date: 04/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.